Bavarian Nordic AS (BV3) Stock Price & Analysis

BV3 Stock Chart & Stats

€33.06-€0.50(-1.49%)

At close: Oct 30 1:00 AM GMT+1

Day’s Range: EUR 32.92 - EUR 33.34
52-Week Range: EUR 22.96 - EUR 34.58
Previous Close: EUR 33.56
Volume: N/A
Average Volume (3M): 370
Market Cap: EUR 2.60B
Enterprise Value: EUR 11.65B
Total Cash (Recent Filing): EUR 1.24B
Total Debt (Recent Filing): EUR 116.96M
Price to Earnings (P/E): 12.4
Beta: 0.51
Next Earnings: Nov 13, 2026 (Est.)
EPS Estimate: 0.71
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bavarian Nordic AS News

Officials confirm community spread of new Mpox strain in Southern CA, NBC says

The California Department of Public Health and local health agencies have confirmed three unrelated cases of a new Mpox strain, known as clade 1, among Southern California residents, NBC reports.

1y agoEBS BVNRY

Bavarian Nordic AS (0DPB) Q4 Earnings Cheat Sheet

Bavarian Nordic AS (0DPB) is scheduled to report 4th quarter earnings on 03/05/2025. Regarding Q4 estimates, Wall Street analysts expect Bavarian Nordic AS to post earnings of DKK8.56 per share.

1y agoBV3 0DPB

0DPB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Bavarian Nordic AS (0DPB) is scheduled to report 3rd quarter earnings on 11/15/2024. Regarding Q3 estimates, Wall Street analysts expect Bavarian Nordic AS to post earnings of DKK4.70 per share.

1y agoBV3 0DPB

Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports

A preprint article posted on September 11 by medRxiv detailed results of a study that showed that vaccine-generated mpox antibodies largely waned 6 to 12 months after administration of Jynneos,

2y agoEBS GOVX

Bavarian Nordic announces commercial availability of VAXCHORA in Canada

Bavarian Nordic announced the commercial availability of VAXCHORA, the only single-dose oral vaccine approved in Canada to protect against cholera, a sudden and serious intestinal infection marked by acute watery

2y agoBVNRY BV3

0DPB Upcoming Earnings Report: What to Expect?

Bavarian Nordic AS (0DPB) is scheduled to report 2nd quarter earnings on 08/22/2024. Regarding Q2 estimates, Wall Street analysts expect Bavarian Nordic AS to post earnings of DKK1.92 per share.

2y agoBV3 0DPB

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Seelos Therapeutics (SEEL), 568% surge in interest Repligen (RGEN),

2y agoEBS MRVI

Applied Materials, H&R Block report quarterly beats: Morning Buzz

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Applied Materials (AMAT) reported better-than-expected Q3 earnings and revenue

2y agoPL FLO

Logistical issues with vaccine pose risk to mpox response, FT reports

Efforts to produce vaccines to aid the mpox international public health emergency in central and east Africa risk is being hobbled by a lack of orders and logistical challenges, Ian

2y agoEBS BVNRY

Bavarian Nordic applies to EMA to use mpox vaccine in adolescents, FT reports

Bavarian Nordic (BVNRY) has applied to the European Medicines Agency to extend its mpox vaccine for use in 12 to 17-year-olds, and if successful, the vaccine could be approved for

2y agoEBS BVNRY

0DPB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Bavarian Nordic AS (0DPB) is scheduled to report 3rd quarter earnings on 11/16/2023, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Bavarian Nordic AS to post earnings

2y agoBV3 0DPB

Bavarian Nordic participates in a conference call with Jefferies

European Healthcare Analysts hold a conference call with management to discuss the company’s vaccine franchise and the outlook for the smallpox/mpox vaccines Jynneos/Imvanex on September 1 at 9 am. Webcast

3y agoBVNRY BV3

Bavarian Nordic participates in a conference call with Jefferies

3y agoBVNRY BV3

Bavarian Nordic participates in a conference call with Jefferies

3y agoBVNRY BV3

BV3 FAQ

What was Bavarian Nordic AS’s price range in the past 12 months?

Bavarian Nordic AS lowest stock price was €22.96 and its highest was €34.58 in the past 12 months.

What is Bavarian Nordic AS’s market cap?

Bavarian Nordic AS’s market cap is €2.60B.

When is Bavarian Nordic AS’s upcoming earnings report date?

Bavarian Nordic AS’s next earnings report is estimated for Nov 13, 2026 (not yet confirmed), which is in 10 days.

How were Bavarian Nordic AS’s earnings last quarter?

Bavarian Nordic AS released its earnings results on Aug 21, 2026. The company reported €1.258 earnings per share for the quarter, beating the consensus estimate of €0.421 by €0.836.

Is Bavarian Nordic AS overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Bavarian Nordic AS pay dividends?

Bavarian Nordic AS does not currently pay dividends.

What is Bavarian Nordic AS’s EPS estimate?

Bavarian Nordic AS’s EPS estimate is 0.71.

How many shares outstanding does Bavarian Nordic AS have?

Bavarian Nordic AS has 79,265,320 shares outstanding.

What happened to Bavarian Nordic AS’s price movement after its last earnings report?

Bavarian Nordic AS reported an EPS of €1.258 in its last earnings report, beating expectations of €0.421. Following the earnings report the stock price went up 11.695%.

Which hedge fund is a major shareholder of Bavarian Nordic AS?

Currently, no hedge funds are holding shares in DE:BV3

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bavarian Nordic AS

Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.

Bavarian Nordic AS (BV3) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	12	6	4
Technical Analysis	3	6	1
Moving Averages	9	0	3

Technical Analysis >

Similar Stocks

Stocks similar to DE:BV3
Company	Price & Change	Follow
GB:0DPBBavarian Nordic AS
GB:HIKHikma Pharmaceuticals
GB:AZNAstraZeneca
GB:GSKGlaxoSmithKline
GB:INDVIndivior
GB:PRTCPureTech Health

Compare DE:BV3 Stocks >

Ownership Overview

7.93% Mutual Funds
83.29% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

BV3 Stock Chart & Stats

Bavarian Nordic AS News

Officials confirm community spread of new Mpox strain in Southern CA, NBC says

Bavarian Nordic AS (0DPB) Q4 Earnings Cheat Sheet

0DPB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports

Bavarian Nordic announces commercial availability of VAXCHORA in Canada

0DPB Upcoming Earnings Report: What to Expect?

Biotech Alert: Searches spiking for these stocks today

Applied Materials, H&R Block report quarterly beats: Morning Buzz

Logistical issues with vaccine pose risk to mpox response, FT reports

Bavarian Nordic applies to EMA to use mpox vaccine in adolescents, FT reports

0DPB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Bavarian Nordic participates in a conference call with Jefferies

Bavarian Nordic participates in a conference call with Jefferies

Bavarian Nordic participates in a conference call with Jefferies

BV3 FAQ

Company Description

Bavarian Nordic AS

Bavarian Nordic AS (BV3) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium